Innovation Theater 4 | Supported By: Eli Lilly and Company

---

Program Description

Join this 45-minute symposium for a practical, case-based discussion on how comprehensive biomarker testing can be effectively integrated into routine care for patients with early-stage non-small cell lung cancer (NSCLC) to ensure appropriate initial treatment decisions.

Moderated by Dr. Gerard Silvestri (pulmonologist), the session will follow a real-world patient journey, prompting discussions around tumor staging, tissue acquisition, and molecular evaluation. A multidisciplinary expert panel featuring Dr. Adam Fox (pulmonologist), Dr. Jessica Donington (thoracic surgeon), and Dr. Charu Aggarwal (thoracic oncologist) will explore current guidelines for the application of biomarker-informed therapy, how to overcome barriers to tissue acquisition and testing practices, results interpretation and implications for treatment decisions, as well as the importance of cross-specialty coordination to improve patient care.

The program will conclude with a panel discussion and audience Q&A, designed to surface real-world workflow challenges and share multidisciplinary strategies that support timely, guideline-aligned biomarker testing practices and treatment decisions for patients with early-stage NSCLC.

MMAT-02712 March 2026 © 2026 Eli Lilly and Company. All Rights Reserved.

Speakers

Moderator: Gerard Silvestri, MD, MS, FCCP
Medical University of South Carolina
Hillenbrand Distinguished University Professor of Thoracic Oncology
Charleston, South Carolina

Presenter: Adam Fox, MD, MS
Medical University of South Carolina
Assistant Professor
Charleston, South Carolina

Presenter: Jessica Donington, MD, MSCR
University of Chicago
Professor of Surgery and Chief of the Section of Thoracic Surgery
Chicago, Illinois

Presenter: Charu Aggarwal, MD, MPH, FASCO
University of Pennsylvania’s Perelman School of Medicine
Leslye M. Heisler Professor of Medicine Section Chief, Thoracic and Head & Neck Cancer
Philadelphia, Pennsylvania